Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of KY1005 (Amlitelimab) in Healthy Volunteers
NCT04449939Phase 1Completed
- Sponsor
- Kymab
- Start
- Jul 2020
- Primary completion
- Nov 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of amlitelimab in atopic dermatitis (AD) (3 arms), sponsored by Kymab. Primary endpoints: Maximum observed concentration at Day 92, Time to maximum concentration at Day 92 and 9 more. Started Jul 2020; status: completed.
02
Drugs
amlitelimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04449939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04449939.